Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
GIR-M52H3 | Mouse | Mouse GITR / TNFRSF18 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
GIR-H82E1 | Human | Biotinylated Human GITR / TNFRSF18 Protein, His,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
GIR-C52H6 | Canine | Canine GITR / TNFRSF18 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
GIR-H82F7 | Human | Biotinylated Human GITR / TNFRSF18 Protein, Fc,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
GIR-H525a | Human | Human GITR / TNFRSF18 Protein, Mouse IgG2a Fc Tag, low endotoxin | ![]() |
![]() ![]() |
![]() ![]() |
GIR-H5254 | Human | Human GITR / TNFRSF18 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
GIR-C5255 | Rhesus macaque | Rhesus macaque GITR / TNFRSF18 Protein, Fc Tag | ![]() |
![]() ![]() |
|
GIR-R5222 | Rat | Rat GITR / TNFRSF18 Protein, His Tag | ![]() |
![]() ![]() |
|
GIR-H5228 | Human | Human GITR / TNFRSF18 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Canine GITR, His Tag (Cat. No. GIR-C52H6) at 2 μg/mL (100 μL/well) can bind Human GITR Ligand, Fc Tag (Cat. No. GIL-H526a) with a linear range of 2-40 ng/mL (QC tested).
The purity of Biotinylated Human GITR Protein, His,Avitag (Cat. No. GIR-H82E1) is more than 95% and the molecular weight of this protein is around 20-30 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Anti-GITR antibody (BMS) | Phase 1 Clinical | Neoplasms | Details | ||
GWN-323 | GWN-323 | Novartis Pharma Ag | Details | ||
MK-1248 | MK-1248 | Merck Sharp & Dohme Corp | Details | ||
REGN-6569 | REGN6569; REGN-6569 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Squamous Cell Carcinoma of Head and Neck | Details |
Ragifilimab | INCAGN-1876; INCAGN-01876; AGEN-1876; CM-701 | Phase 2 Clinical | Agenus Inc, Ludwig Institute For Cancer Research | Neoplasms; Neoplasm Metastasis | Details |
BMS-986156 | BMS-986156 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours; Neoplasms | Details |
This web search service is supported by Google Inc.